Edgewise will pivot to focusing on cardiovascular drugs
Drew Angerer/Getty Images
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71.
The French pharma company Servier said Monday that it would buy Edgewise Therapeutics’ muscular dystrophy business in a deal worth up to $2.65 billion.
The centerpiece of the deal is Edgewise’s sevasemten, which is being studied in a pivotal trial in Becker muscular dystrophy and in a Phase 2 trial in Duchenne muscular dystrophy. The oral drug is designed to protect muscles from the damage that accrues in both rare conditions.
